NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6151.50 123.50 (2.05%)

27.39% Gain from 52W Low

696.1K NSE+BSE Volume

NSE 22 Aug, 2025 3:53 PM (IST)

163,303

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

27 May 2019

6151.50

2.05%

Earnings growth on low base; capex benefits to reflect 2HFY21 onwards

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

concerns. However, EBITDA margin at 34.9% (our estimate: 39.6%) was marginally down by 60bp YoY compared to the fall in GM. This is due to lower other expenses (excluding one-offs), down 130bp YoY, and employee cost, down 60bp YoY (as % of sales). Other expenses had one-offs due to 1) Forex loss of INR74m and 2) Considerably higher amount of INR300m towards CSR. EBITDA at INR4.3b (our est. INR5.2b) grew 13% YoY. Adj. PAT at INR3b (our est. INR4b) grew at higher rate of 25% YoY due to lower tax rate for the quarter. For FY19, Sales/EBITDA/PAT at INR49b/INR19b/INR13b grew 26%/48%/55% on YoY basis....

Divi's Laboratories Ltd.'s price crossed above 200Day SMA today

Divi's Laboratories Ltd.

27 May 2019

6151.50

2.05%

Divis Lab: Margins impacted, Premium valuations

Sell: Divi's Laboratories Ltd.

Recommendation Target

Karvy

Margins impacted, Premium valuations: Divis Labs Net revenues increased by 15.5% YoY to Rs 12.6 bn, which is inlinewith our estimates for the quarter.

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6440.0

Divi's Laboratories Ltd.

25 May 2019

6151.50

2.05%

Divis Labs (REDUCE): FY20 to be a slow growth year downgrade to REDUCE

Sell: Divi's Laboratories Ltd.

BOB Capital Markets Ltd.

FY20 to be a slow growth year downgrade to REDUCE Q4FY19 was a big miss after a solid beat in the last two quarters. Revenue/EBITDA were 8%/23% below estimates. A large part of the miss was due to increase in RM prices, which would take 5-6 months to normalise, and a weak product mix. FY20 should be a year of slower growth (after a high base in FY19), with management guiding for 10% revenue growth and steady margins. This along with full valuations drives our rating cut to REDUCE (vs. ADD) with...

Divi's Laboratories Ltd. has gained 25.52% in the last 1 Year

Divi's Laboratories Ltd.

04 Feb 2019

6151.50

2.05%

Divi's Labs (3QFY19): Valuations unsupportive. Maintain SELL

Sell: Divi's Laboratories Ltd.

Target

HDFC Securities

Maintain SELL with a TP of Rs 1,395 (22x Dec-20E EPS). This is Divis Labs (DIVI) second consecutive quarter with Rs 12bn plus revenues, up from a quarterly run-rate of Rs 9-10bn earlier. Although the management maintains that this is driven by normalization of orders post import alert clearance, there is an uncanny coincidence that the business has gained traction in a quarter where Valsartan API prices soared, and the Rupee fell ~10%.

Divi's Laboratories Ltd. has gained 25.52% in the last 1 Year

Divi's Laboratories Ltd.

04 Feb 2019

6151.50

2.05%

Divi Lab: Revenues and margins outperform

Hold: Divi's Laboratories Ltd.

Recommendation Target

Karvy

Revenues and margins outperform: Divis Lab's Net revenues increased by 29.4% YoY to Rs 13.4 bn, which is higher than our estimates of Rs 10.4 bn for the quarter.

Divi's Laboratories .. has an average target of 6397.40 from 5 brokers.

Divi's Laboratories Ltd.

02 Feb 2019

6151.50

2.05%

Strong revenue growth, better operating leverage drives earnings

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

DIVIs reported strong revenue growth of ~29% YoY to INR13.4b v/s our est. of INR12.2b, partly due to low base of last year. Gross margin expanded ~360bp YoY (+110bp QoQ) to 64.2%. EBITDA margin improved significantly by ~600bp YoY to 39% due to improvement in gross margin and better operating leverage. Employee cost 2 February 2019 increased at a lower rate of 19% YoY to INR1.4b, and other expenses remained stable at INR1.6b. Revenue growth coupled with margin expansion led to ~53% YoY growth in EBITDA to INR5.2b v/s our est.

Divi's Laboratories Ltd. is trading above its 200 day SMA of 6105.5

Divi's Laboratories Ltd.

10 Nov 2018

6151.50

2.05%

Divi Lab: Revenues and margins outperform

Buy: Divi's Laboratories Ltd.

Recommendation Target

Karvy

Revenues and margins outperform: Divis Labs Net revenues increased by 44.4% YoY to Rs 12.9 bn, which ishigher than our estimates of Rs 10.2 bn for the quarter. The Operatingmargins were at 40% in Q2FY19 (much higher than our estimate of 34.7%) asagainst 31% in Q2FY18 on account of better gross margin and lowerexpenditure.

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6440.0

Divi's Laboratories Ltd.

31 Oct 2018

6151.50

2.05%

Divi's Labs (2QFY19): Terrific, but unsustainable. Downgrade to SELL

Sell: Divi's Laboratories Ltd.

Recommendation Target

HDFC Securities

Downgrade to SELL with a TP of Rs 1,345 (22x Sep-20E EPS). Divis Labs (DIVI) reported a blowout quarter, benefitting from a favorable base, currency impact, one time API opportunities and a belated surge of orders post import alert clearance. Revenues grew up 44/29% YoY/QoQ to Rs 12.85bn, EBITDA margin at 40% expanded 887bps, while PAT jumped 92% YoY to Rs 3.98bn. Margin expansion was led by currency benefits and oplev.

Divi's Laboratories Ltd. is trading above its 200 day SMA of 6105.5

Divi's Laboratories Ltd.

31 Oct 2018

6151.50

2.05%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

Revenues grew 44.3% YoY to | 1285 crore against I-direct estimate of | 1012.4 crore led by 1) capacity addition, 2) advantage of supply constraints from China and 3) currency tailwinds EBITDA margins rose 887 bps to 40.0% (I-direct estimate: 36.0%) mainly due to currency tailwinds, operational leverage. EBITDA grew 85.5% YoY to | 514.1 crore (I-direct estimate: | 364.5 crore) Net profit grew 92.3% to | 397.7 crore (I-direct estimate: | 275.1...

Divi's Laboratories Ltd. is trading above its 200 day SMA of 6105.5

Divi's Laboratories Ltd.

29 Oct 2018

6151.50

2.05%

Strong beat on earnings

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

significantly by ~44% YoY to INR12.9b (v/s est. The strong YoY growth was led by (a) normalization of operations post resolution of warning letter, and (b) opportunities due to slowdown in supplies from Chinese competitors. Superior product mix led gross margins to expand by 29 October 2018 ~330bp YoY (+150bp QoQ) to 63%. In addition, improved operating leverage with higher capacity utilization led EBITDA margin to expand ~890bp YoY to 40%. This is the highest margin recorded by the company in the last 18 quarters. Revenue growth coupled with margin expansion led to ~86% YoY growth in EBITDA to INR5.1b (v/s est. Other income saw forex gains of INR528m against INR106m YoY. PAT stood at INR4b up ~92% YoY at INR8.7b (+66% YoY) and PAT at INR6.

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6440.0

Is Divi's Laboratories Ltd. worth buying?

750 Votes:

Buy 78.0%

Sell 15.07%

Hold 6.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf